Wealth Management Partners LLC purchased a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,283 shares of the exchange traded fund’s stock, valued at approximately $547,000.
Several other large investors have also recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of SPDR S&P Biotech ETF during the fourth quarter worth $27,000. Intesa Sanpaolo Wealth Management bought a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter worth $30,000. SHP Wealth Management acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at $31,000. Legacy Wealth Managment LLC ID acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at $32,000. Finally, Smartleaf Asset Management LLC bought a new position in SPDR S&P Biotech ETF during the 4th quarter worth $32,000.
SPDR S&P Biotech ETF Stock Up 0.8%
Shares of NYSEARCA:XBI opened at $147.03 on Wednesday. The firm has a market cap of $9.38 billion, a P/E ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a 12-month low of $82.04 and a 12-month high of $148.76. The business has a fifty day simple moving average of $134.19 and a 200 day simple moving average of $128.13.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
